Kyprolis
NICE turns down Amgen’s multiple myeloma drug
November 9, 2016Research and Development, Sales and Marketing Amgen, Kyprolis, NICE
Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …
EMA opens clinical trial data to public
October 25, 2016Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials
The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …
Amgen’s Kyprolis disappoints in Phase III trial
September 27, 2016Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III
Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …
Amgen says its blood cancer drug gets European backing for extended indication
July 4, 2016Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial
Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
Amgen showcases positive Phase III multiple myeloma drug at ASCO
June 7, 2016Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma
Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
Amgen’s Kyprolis now available to UK multiple myeloma patients
February 12, 2016Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma
Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
Amgen’s Kyprolis gets accelerated FDA review for expanded labelling
September 21, 2015Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma
The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
Treatment shifts away from chemotherapy for multiple myeloma
December 10, 2014Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals
Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …
Speedy FDA nod for Amgen leukaemia drug
December 5, 2014Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia
The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …
Amgen cancer drug fails key test
August 14, 2014Sales and Marketing Amgen, Cancer, Kyprolis, myeloma
Amgen’s new rare cancer drug has failed in a late-stage trial just a year after the US biotech spent $10.4 …
Speedy approval for Onyx’ multiple myeloma drug
July 24, 2012Research and Development, Sales and Marketing FDA, Janssen, Kyprolis, Onyx, Takeda, Velcade
Onyx’ Kyprolis has gained an accelerated approval by the FDA to treat patients with late-stage multiple myeloma. Kyprolis (carfilzomib), a …
